News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.

Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $105.00. They now have an "overweight" rating on the stock.

Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Guggenheim.

Structure Therapeutics (NASDAQ:GPCR) was given a new $102.00 price target on by analysts at The Goldman Sachs Group, Inc..

Form 4 Structure Therapeutics For: Jan 15 Filed by: FMR LLC

Form 8-K Structure Therapeutics For: Dec 30

Form 8-K Structure Therapeutics For: Dec 09

Form 424B5 Structure Therapeutics

Form 4 Structure Therapeutics For: Dec 08 Filed by: FMR LLC

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}